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Abstract
VGF (non-acronymic) was first highlighted to have a role in energy homeostasis through
experiments involving dietary manipulation in mice. Fasting increased VGF mRNA in the
Arc and levels were subsequently reduced upon refeeding. This anabolic role for VGF was
supported by observations in a VGF null (VGF-/-) mouse and in the diet-induced and gold-
thioglucose obese mice. However, this anabolic role for VGF has not been supported by a
number of subsequent studies investigating the physiological effects of VGF-derived pep-
tides. Intracerebroventricular (ICV) infusion of TLQP-21 increased resting energy expendi-
ture and rectal temperature in mice and protected against diet-induced obesity. Similarly,
ICV infusion of TLQP-21 into Siberian hamsters significantly reduced body weight, but this
was due to a decrease in food intake, with no effect on energy expenditure. Subsequently
NERP-2 was shown to increase food intake in rats via the orexin system, suggesting opposing
roles for these VGF-derived peptides. Thus to further elucidate the role of hypothalamic VGF
in the regulation of energy homeostasis we utilised a recombinant adeno-associated viral vec-
tor to over-express VGF in adult male Siberian hamsters, thus avoiding any developmental
effects or associated functional compensation. Initially, hypothalamic over-expression of VGF
in adult Siberian hamsters produced no effect on metabolic parameters, but by 12 weeks
post-infusion hamsters had increased oxygen consumption and a tendency to increased car-
bon dioxide production; this attenuated body weight gain, reduced interscapular white adipose
tissue and resulted in a compensatory increase in food intake. These observed changes in
energy expenditure and food intake were associated with an increase in the hypothalamic
contents of the VGF-derived peptides AQEE, TLQP and NERP-2. The complex phenotype of
the VGF-/- mice is a likely consequence of global ablation of the gene and its derived peptides
during development, as well as in the adult.
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Introduction
VGF is a neurotrophin-induced gene that is widely expressed in neuronal and neuroendocrine
cells. The VGF gene encodes a 68kDa polypeptide which is cleaved by prohormone conver-
tases (PCs) into multiple smaller peptides and released upon depolarising stimuli [1–4]. Whilst
VGF mRNA is expressed in many regions of the nervous system, the highest concentrations of
VGF immunoreactivity are found in the ventromedial hypothalamus, in particular the arcuate
nucleus (Arc) and paraventricular nucleus (PVN) [5–7].
VGF was first highlighted to have a role in energy homeostasis through experiments involving
dietary manipulation in mice. Fasting increased VGF mRNA in the Arc, and levels were subse-
quently reduced upon refeeding [8]. This anabolic role for VGF was supported by observations
in a VGF null (VGF-/-) mouse [8]. VGF-/- mice are small, lean, hypermetabolic and hyperactive.
They consume more food per gram body weight than wildtype littermate controls, and display
increased oxygen consumption and locomotor activity [8]. Interestingly, ablation of the VGF gene
blocked the development of obesity in diet- and gold-thioglucose mice and VGF-/- mice crossed
with the (Ay/a) (agouti) mouse, whilst weight gain was attenuated in the ob/ob mouse [9, 10].
However, this anabolic role for VGF has not been supported by a number of subsequent stud-
ies investigating the physiological effects of VGF-derived peptides. Intracerebroventricular
(ICV) infusion of TLQP-21 increased resting energy expenditure and rectal temperature in mice
and protected against diet-induced obesity [11]. Similarly, ICV infusion of TLQP-21 into Sibe-
rian hamsters significantly reduced body weight, but this was due to a decrease in food intake,
with no effect on energy expenditure [12]. Subsequently NERP-2 was shown to increase food
intake in rats via the orexin system (body weight data not included) [13], suggesting opposing
roles for these VGF-derived peptides. More recently, VGF expression was shown to be depen-
dent upon metabolic state in rats [14], whilst in the Siberian hamster, TLQP immunoreactivity
was found to be expressed throughout the hypothalamus (the preoptic area, supraoptic nucleus,
suprachiasmatic nucleus and median eminence) in axons and perikarya [15]. A possible explana-
tion for the differences observed between the functional studies utilising the different VGF
derived peptides [11, 12] and the genetic studies in the VGF-/- mouse [8] is that global ablation
of the gene produces an errant phenotype, possibly due to VGF having pleiotropic roles during
development and adult life, as recently reviewed [4].
The aim of this study was therefore to better understand the role of VGF in the regulation of
energy homeostasis by utilising a recombinant adeno-associated viral vector (AAV) to over-
express VGF in the hypothalamus of adult male Siberian hamsters, thus avoiding any develop-
mental effects or associated functional compensation. We previously demonstrated the feasibility
of using the viral 2A sequence in combination with AAV for the long-term over-expression of
VGF and fluorescent reporter (eGFP) genes in the hypothalamus of the Siberian hamster [16].
Methods
Animals
Male Siberian hamsters (Phodopus sungorus) aged 3 months were taken from a colony main-
tained by the University of Nottingham (Ebling, 1994). Hamsters were housed in individual
cages under controlled temperature (21±1˚C) and on a reverse photoperiod of 16h light/8h
dark (lights off at 11:00h), with ad-libitum access to food and water, unless otherwise stated.
The diet was standard laboratory chow comprising of 19% extruded protein and 9% fat (Tek-
lad 2019, Harlan, UK). All animal procedures were approved by the University of Nottingham
Animal Welfare and Ethical Review Board and were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 (project licence PPL 40⁄3604).
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Synthesis of construct and viral particles
Synthesis of constructs and viral particles, including in vitro and in vivo validation, has been
described previously [16]. In brief, pAAV-CBA-VGF-2A-eGFP (subsequently called pAAV-
VGF-GFP) was constructed by removing the AgRP-IRES-eGFP from the plasmid pAAV-
CBA-AgRP-IRES-eGFP-WPRE (a kind gift from Dr Miguel Sena-Esteves (University of
Massachusetts, Worcester, USA; [17]) and inserting VGF-2A-eGFP. The plasmid was then
sequenced to confirm removal of AgRP-IRES-eGFP and insertion of VGF-2A-eGFP in the
correct orientation. Following in vitro validation in the SH-SY5Y neuroblastoma cell line, the
pAAV-VGF-GFP plasmid was packaged into AAV-2 by Vector BioLabs (PA, USA) and the
packaged AAV-GFP control was purchased from Vector Biolabs (PA, USA).
Infusion of viral constructs
Animal surgical procedures were carried out as previously described [16, 17]. Briefly, animals
were placed in a Kopf stereotaxic frame (David Kopf Instruments, NY, USA) with the incisor
bar positioned level with the interaural line under general anaesthesia (0.5–2.5% isoflurane).
Analgesia was maintained via subcutaneous injection of carprofen (50 mg/kg Rimadyl, Pfizer,
Kent, UK). Using the sutures confluence bregma as a landmark, a small hole was drilled on
midline and the dura mater was pierced just lateral to the mid-sagittal sinus. A drawn glass
capillary microinjector (30-micron tip diameter) was lowered to the correct location. Using a
Nanolitre Injection system (WPI, Stevenage, UK) 200nl of the viral vector (AAV-GFP, n = 3
or AAV-VGF-GFP, n = 4) was directed towards the PVN (anteroposterior +0.03, mediolat-
eral ± 0.03, dorsoventral -0.58 (co-ordinates from [18]). Infusions were over two minutes,
however the glass microinjector was kept in place for an additional 5 minutes to allow for dif-
fusion and prevention of backflow through the cannula track, and the incision was closed
using Michel clips. The surgically-prepared Siberian hamsters were allowed a seven day recov-
ery period, during which they were handled on a daily basis, received analgesia and had access
to a palatable diet consisting of soaked Teklab diet. Over-expression of VGF mRNA and eGFP
was previously described (16).
Metabolic gases and feeding behaviour
Multiple respiratory and feeding behaviour parameters were measured using a Comprehen-
sive Lab Animal Monitoring System (CLAMS; Linton Instrumentation, Linton, UK, and
Columbus Instruments, Columbus, OH, USA) as described previously [16, 17, 19]. This is
an open-circuit calorimeter configured for small rodents, where the rodents were individu-
ally housed with food hoppers in the centre of each cage containing chow ground into a
rough powder, and dropper-style water bottles. Metabolic parameters measured included
oxygen consumption (VO2) and carbon dioxide production (VCO2), normalised over the
estimated lean mass (BW 0.75) due to the change in body composition, such that the energy
expenditure (EE) and respiratory exchange ratio (RER) could be calculated as previously
described [20]. Feeding behaviour parameters measured included the timing and duration
of feeding, individual meal size, and total food intake per unit time. A meal equal to or
greater than 0.02g is considered to be a feeding bout. Ambulatory (locomotor) activity was
also measured continuously using two sets of infrared beams traversing each cage that mea-
sure linear and vertical movement. The system was operated with an air intake of 0.6 L⁄min
for each chamber, and an extracted outflow of 0.4 L⁄min. All measurements were taken at an
ambient temperature of 21–22˚C.
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Effect of over-expression of VGF in the hypothalamus of Siberian hamsters
Three groups of adult male Siberian hamsters were utilised. Group 1 received a bilateral infu-
sion of 200nl of either AAV-GFP (n = 3, 1 x 1013 genomic copies/ml, one animal from this
group was euthanized due to poor recovery from anaesthesia) as control or AAV-VGF-GFP
(n = 4, 7.2 x 1012 genomic copies/ml) directed towards the PVN. We have previously shown
this to be an effective strategy for infecting the hypothalamus, an area of high VGF expression
[17]. After recovery bodyweight and food intake were measured weekly in the home cage. 2
weeks post viral infusion, Group 1 were euthanized by injection of pentobarbital sodium
(Euthatal; Rhone Merieux, Harlow, UK) and organs removed, weighed and immediately snap
frozen at -80˚C. Group 2 received the same vectors as described, were subjected to CLAMS
analysis for 48 hours (the first 24 hours were discarded as a period of habituation; the second
24 hours were used for analysis and presented here, a strategy successfully utilised in[16, 17,
19]) at 2 and 12 weeks post viral infusion and subsequently euthanized by injection of pento-
barbital sodium and organs removed, weighed and immediately snap frozen at -80˚C. Group 3
received the same vectors as described (n = 6 per treatment) and 32 weeks post viral infusion
were euthanized by injection of pentobarbital sodium and the brains removed and immedi-
ately snap frozen at -80˚C [16]. eGFP visualization and in situ hybridization were performed as
previously described [16]. Briefly, antisense transcripts were generated from the pSC-B-AMP/
KAN plasmid (containing VGF cDNA) using T7 polymerase (NEB, USA) in the presence of
digoxigenin(DIG)/fluorescein-12-uridine-5-triphosphate (a kind gift from Dr Dylan Sweet-
man, UoN). Riboprobes were purified on a spin column. Slides containing 20μm coronal sec-
tions were fixed in 4% PFA/0.1% gluteraldehyde before treatment with proteinase K (10μg/
ml). Slides were incubated with hybridization solution containing riboprobe for 6h at 65˚C.
Post-hybrisidation, sections were washed with hybridization solution for 10mins at 65˚C, fol-
lowed by two washes with maleic acid buffer containing 0.1% Tween-20 (MABT, pH 7.5). Sec-
tions were subsequently blocked in MABT/2% Roche blocking agent for 1h and subsequently
incubated overnight with anti-DIG conjugated to alkaline phophatase (1:2000) at 4˚C. Slides
were washed with MABT for 1h followed by an overnight incubation in MABT at 4˚C. To per-
form the colour reaction, sections were washed with 1-methyl-5-thiotetrazole (NMTT) con-
taining nitroblue tetrazolium (NBGT) and 5-bromo-3-indocyl-phosphate (BCIP). The colour
reaction was stopped by washing the sectionsin 5x TBST (1xTBS, 0.1% Tween 20, 0.2mM
sodium azide) overnight at 4˚C. This process was repeated the following day to intensity the
signal and reduce background. Images were captured using a Lecia DMRB microscope (Ger-
many) and OpenLab software (UK). To determine VGF mRNA and GFP expression, slides
were scored for the density of signal in the hypothalamic region reflecting hybridization of the
VGF probe and GFP signal by an observer who was blind to the treatment: 0 = no hybridiza-
tion, 1 = a few cells expressing VGF mRNA, 2 = moderate VGF mRNA expression, 3 = abun-
dant VGF mRNA [21].
Peptide quantification
Quantification of the VGF peptides including, TLQP, AQEE and NERP-2 was carried out via
ELISA on whole hypothalamic samples. The antibodies used in each assay were produced
against the following peptides: the N-terminal decapeptide of TLQP-21 (rat VGF556-565),
AQEE-30 (rat VGF586-595), and the C-terminal nonapeptide of NERP-2 (rat VGF342-350)
that contains an amide group at its C-terminus, conjugated with bovine thyroglobulin or key-
hole limpet hemocyanin via an additional cysteine at the C-terminus (TLQP, AQEE) or N-ter-
minus (NERP-2). Each antibody has a high affinity for the corresponding VGF peptide, but
other cleaved peptides encompassing the sequence could also be recognised, as previously
Central over-expression of VGF
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observed with TLQP antiserum which binds to TLQP-21, but also TLQP-62 [15]. The ELISA
was carried out as previously described [15]. Briefly, multi-well plates coated with the specific
synthetic VGF peptides were incubated with the VGF antisera in parallel with tissue samples
and standards (the same synthetic peptides used for immunizations) followed by the relevant
biotinylated secondary antibodies (Jackson, West Grove, PA, USA) and the streptavidin-per-
oxidase conjugate (Biospa, Milan, Italy). Each VGF assay was characterized using various syn-
thetic peptides (see Table 1).
Statistical analysis
Descriptive statistics (mean±SEM) were generated using GraphPad Prism (version 6.0, Graph-
Pad Software Inc., San Diego, CA, USA). Body weight, home food intake, data obtained from
the CLAMS apparatus and peptide quantification were analysed using two-way repeated mea-
sures ANOVA followed by a post hoc Bonferroni test. Data on organ weights at the end of the
study were analysed using a Student’s unpaired t-test. Scores were analysed by a Kruskal-Wallis
test with post-hoc Dunn’s tests for multiple comparisons. Statistical significance was accepted at
p<0.05.
Results
Over-expression of VGF mRNA
Post mortem analysis revealed high levels of GFP expression in both groups, however, VGF
mRNA expression was lowly expressed in the hypothalamus of AAV-GFP animals. Animals
treated with AAV-VGF-GFP demonstrated high levels of hypothalamic VGF mRNA which
corresponded to the pattern of GFP expression (see S1 Fig).
Effect of over-expression of VGF on body weight, food intake and
ingestive behaviour
Bilateral infusion of AAV-VGF-GFP into the hypothalamus of Siberian hamsters had no effect
on body weight at 2 weeks post infusion compared to AAV-GFP control (Fig 1A), however
over the 12 week experimental period an attenuation in the increase in body weight was
observed (time vs. treatment interaction F = 5.037, p< 0.001). Siberian hamsters infused with
AAV-GFP control increased in bodyweight by an average 12.6% at the end of the 12 week
study period whereas those infused with AAV-VGF-GFP only increased by an average of 1.0%
(Fig 1A).
Table 1. VGF assay characterization. IC50: 50% inhibitory concentration; CV1 and CV2: intra- and inter-assay variation, respectively; h: human; r: rat. 1pep-
tide used for plate coating and assay standard. 2Des-amidated peptide and 3peptide with an additional glycine residue at the C-terminus were used to test for
cross reactivity. All of the antisera used for the tissue VGF quantification showed 100% cross-reactivity with the corresponding peptides.
Assay Peptide IC50 pmol/ml CV1 CV2 Cross-reactivity
TLQP rVGF556-564 (TLQPPASSR)1 1.1 3–5 6–10 100
rVGF555-564 3.5
rVGF556-567 (TLQP-11) 122
rVGF556-576 (TLQP-21) 183
AQEE hVGF586-595 (AQEEAEAEER)1 3 3–4 10–13 100
NERP-2 rVGF312-350-NH2 1 1 3–5 5–8 100
rVGF342-350-NH2 73
rVGF342-350 (des-amide)2 <0.001
rVGF342-351 (“G” extended)3 <0.001
doi:10.1371/journal.pone.0172724.t001
Central over-expression of VGF
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Over the 12 week experimental period a significant increase in cumulative food intake was
observed in the AAV-VGF-GFP group compared to AAV-GFP control group (time vs. treat-
ment interaction F = 10.91, p<0.0001, Fig 1B). Analysis of the pattern of ingestive behaviour
over a 24 hour period at 2 weeks post infusion revealed no effect of treatment on meal dura-
tion, frequency and intake (Fig 1C, 1E and 1G, respectively). At 12 weeks post infusion,
AAV-VGF-GFP treated animals had a significant increase in meal duration (Fig 1D effect of
treatment F = 8.385, p<0.05), but there was no significant change in meal frequency (Fig 1F).
Food intake was significantly increased (Fig 1H, effect of treatment F = 5.784, p< 0.05).
Effect of over-expression of VGF on metabolic parameters
Analysis of metabolic parameters at 2 weeks post bilateral infusion with AAV-VGF-GFP
revealed no effect of treatment at this stage compared to the AAV-GFP control group (Fig 2A–
2E). However, by 12 weeks post infusion there was a significant increase in VO2 in the
AAV-VGF-GFP treated group compared to the AAV-GFP control animals (effect of treat-
ment = 8.854, p< 0.05; Fig 2F), while there was a trend for an increase in VCO2 (effect of treat-
ment F = 5.706, p = 0.06; Fig 2G). The effect was primarily in the dark phase, with VO2 being
13.4% higher in the AAV-VGF-GFP treated group compared to the AAV-GFP control group.
This resulted in a significant increase in energy expenditure in the AAV-VGF-GFP control
group (effect of treatment F = 7.968, p<0.05; Fig 2H). No effects on RER (Fig 2I) or ambula-
tory activity (Fig 2J) were observed.
Effect of over-expression of VGF on organ weight
There was no effect on organ or tissue weight in Siberian hamsters bilaterally infused with
AAV-VGF-GFP (compared to those infused with AAV-GFP as a control) 2 weeks post infu-
sion (Table 2). However, at 12 weeks post infusion, there was an increase in the weight of inter-
scapular brown adipose tissue (p<0.05, Table 2) and a decrease in weight of interscapular
white adipose tissue (p< 0.05, Table 2) in the AAV-VGF-GFP group. There were no signifi-
cant effects on the wet weights of the epididymal white adipose tissue and the liver (Table 2).
Effect of over-expression of VGF peptide levels in the hypothalamus
Bilateral infusion of AAV-VGF-GFP for two weeks (Group 1) did not result in any changes in
the levels of VGF derived peptides TLQP, AQEE and NERP-2 compared to those infused with
AAV-GFP, however by 12 weeks an increase in all three peptides was apparent (Fig 3A–3C,
time vs. treatment interactions F = 5.02, 5.07 and 3.78 respectively, p<0.05).
Discussion
Hypothalamic over-expression of VGF in adult Siberian hamsters produced a complex pheno-
type; at 2 weeks post infusion there was no effect on metabolic parameters. AAV-2 has a rela-
tively slow onset of transcription but has been previously shown to efficiently and stably over-
express trans- and reporter-genes [17, 22, 23]. By 12 weeks hamsters had increased oxygen
consumption and a tendency to increased carbon dioxide production; though no significant
Fig 1. Hypothalamic over-expression of VGF attenuates body weight gain, whilst increasing food intake; a
consequence of increased meal duration. Adult male Siberian hamsters received bilateral infusion of either AAV-GFP
(control, GFP) or AAV-VGF-GFP (treated, VGF), with bodyweight (in grams) (A) and food intake (grams per gram body
weight) (B) determined over the 12 weeks in home cages; while meal duration (C and D) and meal frequency (E and F) were
determined over a 24hr period in metabolic cages at 2 (C and E) and 12 weeks (D and F) post-infusion. Values are group
mean ±SEM, n = 3–4 per treatment, interaction **** p<0.0001; effect of treatment * p<0.05.
doi:10.1371/journal.pone.0172724.g001
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change in RER and therefore no evidence that substrate utilization (carbohydrate vs. fat oxida-
tion) was affected. The increase in oxygen consumption 12 weeks post viral infusion was not
due to an increase in locomotor activity, as this was similar in AAV-GFP and AAV-VGF-GFP
infused animals. We infer that the significant increase in oxygen consumption, and therefore
energy expenditure, 12 weeks post viral infusion, particularly during the dark phase, was the
main driver for the attenuated body weight gain in AAV-VGF-GFP infused animals. Indeed,
hypothalamic over-expression of VGF reduced interscapular white adipose tissue weights, but
increased interscapular brown adipose tissue weights, 12 weeks post infusion, which may
potentially account for the increased energy expenditure. Interestingly, externally located
WAT depots are relatively spared in response to photoperiod change in the Siberian hamster;
epididymal WAT demonstrates proportionally greater decreases [24]. This suggests differential
sympathetic neural control in WAT depots in this species. There was a small but significant
increase in food consumption measured in the home cage in AAV-VGF-GFP infused animals.
The increase in cumulative food intake was apparent 3 weeks post infusion and persisted for the
12 week experimental period; this resulted in significantly increased cumulative food intake
(grams per g body weight) in the AAV-VGF-GFP infused group. This reflected increased meal
duration and intake, as measured in CLAMS at 12 weeks post viral infusion, since meal fre-
quency was unaffected. There was no effect on these behavioural parameters 2 weeks post infu-
sion. We infer that these increases in food intake were a compensatory mechanism to limit
weight loss and maintain energy stores. These observed changes in energy expenditure and
food intake were associated with an increase in the hypothalamic contents of the VGF-derived
peptides, AQEE, TLQP and NERP-2. These peptides have been shown to be involved regulating
energy homeostasis, since ICV administration of TLQP-21 has been shown to reduce food
intake in Siberian hamsters [12] and increase energy expenditure in mice [11], while ICV infu-
sion of NERP-2 in rats was shown to increase energy expenditure and food intake via the orexin
system [13], suggesting opposing roles for these two distinct VGF derived peptides. These func-
tional studies conducted with VGF derived peptides in multiple species largely support the phe-
notype produced by hypothalamic over-expression of VGF in the Siberian hamster. Both of
these VGF derived peptides (TLQP and NERP-2) were increased 12 weeks post viral infusion
with AAV-VGF-GFP and may contribute to the observed increase in energy expenditure. Inter-
estingly, TLQP-62 is the most prominent VGF derived peptide [3], whilst AQEE-30 increases
Fig 2. Hypothalamic over-expression of VGF increases oxygen consumption (VO2) which is unrelated
to ambulatory activity. 24 hour profiles of oxygen consumption (VO2) (A and F), carbon dioxide production
(VCO2) (B and G), energy expenditure (C and H), respiratory exchange ratio (RER) (D and I) and ambulatory
(locomotor) activity (E and J) of adult male Siberian hamsters measured in metabolic cages at 2 (A-E) and 12
weeks (F-J) post-infusion with either AAV-GFP (control, GFP) or AAV-VGF-GFP (treated, VGF) viral vectors.
Values are group mean ±SEM, n = 3–4 per treatment, effect of treatment * p<0.05.
doi:10.1371/journal.pone.0172724.g002
Table 2. Hypothalamic over-expression of VGF in Siberian hamsters increases BAT weight and reduces interscapular white adipose tissue
weight. Mean (± SEM) wet tissue weight (mg per g BW) in Siberian hamsters receiving bilateral AAV-GFP or AAV-VGF-GFP at 2 and 12 weeks post viral
infusion. * p < 0.05.
Group Treatment LIVER (mg/g BW) eWAT (mg/g BW) iBAT (mg/g BW) iWAT mg/g BW)
Group 1 (week 2) AAV-GFP 34.9 ± 2.2 25.6 ± 0.7 2.6 ± 0.3 17.4 ± 3.5
AAV-VGF-GFP 32.9 ± 1.4 27.5 ± 0.6 2.5 ± 0.2 16.3 ± 2.1
Group 2 (week 12) AAV-GFP 36.1 ± 1.9 23.6 ± 1.6 2.9 ± 0.2 24.4 ± 3.4
AAV-VGF-GFP 38.0 ± 3.7 22.8 ± 0.5 4.6 ± 0.4* 17.4 ± 3.5*
eWAT = epididymal white adipose tissue; iBAT = intrascapular brown adipose tissue; iWAT = intrascapular white adipose tissue
doi:10.1371/journal.pone.0172724.t002
Central over-expression of VGF
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Fig 3. Hypothalamic over-expression of VGF resulted in time-dependent increases in the VGF-derived
peptides, TLQP, AQEE and NERP-2, in the hypothalamus of adult male Siberian hamsters.
Hypothalamic peptide levels (nmol/g protein) of TLQP (A), AQEE (B) and NERP-2 (C) in adult hamsters
bilaterally infused with either AAV-GFP (control, GFP) or AAV-VGF-GFP (treated, VGF) viral vectors at 2 or
12 weeks post infusion. Values are group mean ±SEM, n = 3–4 per treatment, interaction *p<0.05.
doi:10.1371/journal.pone.0172724.g003
Central over-expression of VGF
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upon high caloric feeding in rats [25] and analysis of hSNP mice (where the C terminal of VGF
is deleted) suggests AQEE-30 may have a positive effect on energy homeostasis (as these mice
have reduced adiposity) or act as functional antagonists of TLQP-21 under physiological condi-
tions [26]. However, this ablation is once again associated with a robust increase in oxygen con-
sumption, food intake and locomotor activity; a consequence of hyperactivity [26].
Interestingly, hypothalamic knockdown of VGF leads to metabolic disturbances in male
mice [27]. Hypothalamic knockdown of VGF, using a Cre-loxP system, resulted in weight gain
and decreased body temperature, oxygen consumption, RER and locomotor activity. Whilst
food intake was unaffected, glucose tolerance was impaired. These effects resulted in increased
adiposity and reduced UCP1 protein in BAT, a phenotype that is mostly opposite (and there-
fore in agreement with) the phenotype described here for hypothalamic VGF over-expression
and largely consistent with the proposed role of TLQP-21 in adult mice [11].
Interestingly, these effects of VGF over-expression are analogous to studies of cocaine
amphetamine regulated transcript (CART), which has orexigenic and anorectic effects depen-
dent upon its site of hypothalamic ICV infusion [28–30]. Furthermore, the phenotype pro-
duced by the hypothalamic over-expression of VGF in the Siberian hamster is very similar to
transgenic mice that over-express orexin, with orexin having been shown to mediate the effects
of NERP-2 in rats [13, 31]. Interestingly, these orexin transgenic mice are resistant to diet-
induced obesity as a result of increased energy expenditure despite significantly increased
daily food intake [31].
It is also of note that VGF gene expression is photoperiodically regulated, with short day
length (SD) which leads to reduced adiposity, associated with a decrease in expression of VGF
in the Arc but dramatically higher expression in the dorsomedial posterior Arc of Siberian
hamsters [21, 32]. Given the nature of the phenotype produced by hypothalamic over-expres-
sion of VGF in Siberian hamsters in long day length (LD) described here, there is a need to
determine peptide levels in specific hypothalamic nuclei to further elucidate their role in sea-
sonal adaptation.
The findings of the studies presented here are largely in agreement with those of Bartolo-
mucci et al. [11] and Jethwa et al. [12], which both utilised the VGF derived peptide TLQP-21,
as well as the hypothalamic knockdown studies conducted by Foglesong et al. [27]. However,
they are in contrast with the VGF-/- and hSNP mice, which are lean, hypermetabolic and
hyperactive [8, 26]. The complex phenotype of the VGF-/- mice [8] is a likely consequence of
global ablation of the gene and its derived peptides during development, as well as in the adult.
Hahm et al. [8] postulated that an increase in VGF expression in the hypothalamus of mice
would increase food intake and body weight, while energy expenditure would decrease, result-
ing in an obese phenotype. Indeed germline over-expression of VGF in mice modestly
increased body weight and food intake, whilst reducing locomotor activity [26]. The current
study demonstrates that over-expression of VGF in the hypothalamus of the Siberian hamster
actually results in the opposite phenotype, increasing energy expenditure and reducing body
weight gain, despite increasing food intake, highlighting the complexity of VGF and its derived
peptides during development and adulthood.
Supporting information
S1 Fig. Hypothalamic over-expression of VGF mRNA corresponds to GFP expression in
AAV-VGF-GFP treated animals. Hypothalamic VGF mRNA is increased in AAV-VGF-GFP
treated animals and is limited to a few cells in the AAV-GFP group (if detected) despite high
levels of GFP expression. Values are group mean ±SEM, n = 6 per treatment.
(PDF)
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